Natdac

Natdac - Daclatasvir - 60mg

It is indicated for the treatment of adult patients with genotype 3 chronic HCV infection, including those with cirrhosis. Daclatasvir is taken orally once daily and can be used in combination with other antiviral agents, such as sofosbuvir or simeprevir. In clinical trials, daclatasvir was found to be safe and well tolerated, with few adverse effects reported. The most common side effects were headache and fatigue. Daclatasvir has been shown to be effective in eliminating HCV from the blood stream, resulting in cure rates of up to 94%. Therefore, daclatasvir represents a valuable new addition to the armamentarium against HCV infection.

Since its approval by the FDA in July 2015, daclatsavir has become an important tool against hepatitis C virus infections. This drug is a direct-acting antiviral agent that inhibits replication of the virus by blocking one of its proteins called NS5A. Daclatsavir can be used alone or in combination therapy with other drugs such as sofosbuvir or simeprevinvfor adults infectedwith genotype 3 chronic hepatitis C virus infections – even thosewith cirrhosis. Clinical studies have shownthat this drugis safeand well toleratedin most peopleand results infrequently reported adverse effects like headaches andfatigue. Additionally, data suggests thatdaclatsavir maybe effective at clearinghepatitis CVirus fromthe bloodstreamin up too 94%of cases – making it an important addition totreatment options for this serious disease

Frequently asked Questions